⭐ Featured Analysis
Retatrutide Delivers 18.8% Weight Loss in Type 2 Diabetes at 80 Weeks
In TRIUMPH-2, retatrutide 12 mg cut body weight 18.8% over 80 weeks in adults with type 2 diabetes, versus 5.1% on placebo.
Read Full Analysis →Newest Analyses
Pharmacokinetics / TDM96% of Vancomycin-Treated ICU Patients Qualified for TDM, Yet None Received It
Women's Health / ReproductiveMigraine and Contraception: Aura Status and Vascular Risk Drive Method Choice
Endocrinology / Diabetes / ObesityOral Orforglipron Added to Titrated Glargine Lowers HbA1c Without More Hypoglycemia
★ Editor's Picks
INFINITY: Finerenone Benefits Extend to Non-Diabetic Chronic Kidney DiseaseNephrology / Renal Pharmacy
Retatrutide Delivers 18.8% Weight Loss in Type 2 Diabetes at 80 WeeksEndocrinology / Diabetes / Obesity
Stopping Anticoagulation at Nursing Home Entry: No Stroke Signal, Higher MortalityAnticoagulation / Hematology
💊 Clinical Pearl of the Week
96% of Vancomycin-Treated ICU Patients Qualified for TDM, Yet None Received It Pharmacokinetics / TDM
A MRSA-only trigger would have captured only about 8% of this cohort, so rule-based alerts should include CRRT, acute kidney injury, vasopressor use, sepsis and concurrent nephrotoxins.
⚡ Practice-changing
- EBMT Harmonizes Viral CNS Infection Care After HSCT and CAR T-Cell Therapy
- ICRAKI: Initial Intermittent Dialysis Linked to Higher Mortality Than Continuous Therapy
- Chemotherapy-Free Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Adult Ph-Positive ALL
- BSR 2026 Polymyalgia Rheumatica Guideline: Bone Protection, Faster Tapers, Early Methotrexate, IL-6R Blockade
Most-read this week
2AASLD/IDSA 2025 Hepatitis B Guideline Shifts From Guidance to RecommendationsInfectious Disease / Antimicrobials
3AGNP 2026 Update Overhauls Therapeutic Drug Monitoring in NeuropsychopharmacologyPharmacokinetics / TDM